News - 24 Oct 2023
Q3 2023: New strategic focus and improved sales trend
Important events during the third quarter
- Net sales increased by 8% (6% adjusted for currency effects) to SEK 156 m (145).
- The EBITDA margin amounted to 18% (25) or 20% adjusted for items affecting comparability.
- New strategic focus areas and financial targets.
- New clinical study in metabolic health shows clear benefits with Probi's bacterial strains, which opens up a new health area.
- Third clinical trial of HEAL9™ published, strengthens evidence of improved cognitive performance.
Read the entire report here.